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Cyclic GMP-linked pathway for renin secretion. The role of cGMP as a
second messenger for renin secretion is contentious. This was investigated
using a superfused collagenase.dispersed rat kidney cortex cell prepara-
tion devoid of indirect influences on renin secretion. Nitroprusside,
atriopeptin II and 8-Br-cGMP all increased renin release but the dose-
response relationships were biphasic. At low dose ranges there was a
positive correlation between increasing drug concentration and renin
secretion, but at high drug concentrations, a negative correlation was
apparent. Methylene blue, a guanylate cyclase inhibitor, also suppressed
baseline renin release at 10 and i0 M, but stimulated release at 10
M. Using mid-range drug concentrations, the cOMP specific phosphodi.
esterase inhibitor MB22948 potentiated renin release in response to
nitroprusside and 8-Br-cGMP. Inhibition of guanylate cyclase with either
methylene blue or LY83583 attenuated renin release in response to
nitroprusside, but, as expected, had no effect on 8-Br-cGMP induced
release. We conclude that, under physiological conditions, cGMP is a
stimulatory second messenger for renin release. This activity is mimicked
at low dose ranges by 8-Br-cGMP, nitroprusside and atriopeptin II. In
response to high doses of these drugs an unknown inhibitory pathway is
activated and this opposes, in a dose-related manner, the stimulatory
actions of cGMP for renin release.
Nitric oxide (NO) and nitrovasodilator drugs activate soluble
guanylate cyclase and thus increase the formation of cGMP.
There are conflicting reports concerning the direct effects of this
pathway in the regulation of renin secretion from juxtaglomerular
(JG) cells. In vivo, drugs which alter cGMP formation may alter
many aspects of renal function, vascular tone, baroreceptor
sensitivity and neural activity. However, studies using in vitro
preparations have also failed to provide consistent results. Some
authors [1, 2], using isolated perfused kidneys, report that NO and
cGMP have a stimulatory effect on renin release, whereas others
[3—5], on the basis of studies using kidney cortex slices, suggest
that the NO-cGMP pathway is inhibitory for renin release. As
both kidney slices and isolated perfused kidneys retain an intact
microanatomy, drug responses of JG cells may still be mediated
through indirect effects on adjacent cell populations. A study
carried out using primary cultures of mouse JG cells [6] has shown
a biphasic effect: NO-linked inhibition of renin release in the first
hour followed by a stimulation over the succeeding 20 hours. The
time course of this study is, however, quite different to the acute
responses studied by other groups.
We used a superfused collagenase-dispersed rat kidney cortex
cell preparation [7] to investigate acute cGMP-linked renin
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secretion. Indirect influences mediated by attached cell popula-
tions were thus eliminated. Two very important aspects of our
study were that, in contrast to other studies, a wide range of drug
doses was used, and that a superfusion protocol was used. The
data obtained supports the concept that cGMP is fundamentally a
stimulatory second messenger for renin release, but bell-shaped
drug dose-response relationships were obtained. High doses of
drugs associated with increased intracellular [cGMP] caused
markedly submaximal increases in renin release. This suggests the
progressive activation, by high drug doses, of an inhibitory path-
way for renin secretion which opposes the cGMP-linked stimula-
tion of release.
Methods
Details of the methods used have been published previously [7].
Briefly, fresh rat kidney cortex tissue was chopped and digested
with collagenase. Cells were harvested three times during the
digestion to prevent prolonged exposure to the enzyme. They
were then filtered successively through gauzes of 250 m, 100 jm
and 60 p.m mesh to ensure separation of undigested fragments of
tissue. This technique also led to an enrichment of the JO cell
preparation by elimination of a significant proportion of renal
tubule fragments. Approximately iO cells were layered onto
Biogel P2 in each of four PTFE chambers and superfused with
Krebs Ringer bicarbonate buffer containing 0.2% glucose and
0.2% bovine serum albumin (Fraction V; Miles). Cells were
allowed to equilibrate for 90 minutes and then 40 five-minute
superfusate samples were collected. During this time each cell
preparation was challenged on four occasions for 10 minutes with
a drug dose. Parallel columns, using different aliquots of the same
cell preparation, were used to test agonist antagonist, thereby
eliminating variation in cell responsiveness between preparations
as a factor when interpreting results.
Renin concentration in the superfusate was measured by radio-
immunoassay of angiotensin I generated during incubation with
excess renin substrate prepared from the plasma of sheep six days
after bilateral nephrectomy. The same substrate preparation was
used for all of the samples in any one series of experiments.
Mean basal renin release before and after drug stimulation was
assigned 100% and mean renin release in response to stimulation
was expressed as a response ratio (RR), that is, as a percentage of
baseline release. A paired Student's t-test was used to compare
drug responses with basal renin release.
The sources of the drugs used were as follows: 8-Br-cGMP
(Sigma), sodium nitroprusside (NP) (BDH) atriopeptin II (APII)
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Fig. 1. Wide range dose-response relationship for 8-Br-cGMP induced renin
release. Results are shown as mean SCM.
(Sigma), methylene blue (MeB) (Michrome), LY83583 (Eli Lilly),
MB22948 (Rhone-Poulenc).
Results
Figure 1 shows responses to a range of concentrations (10—11 to
iO M) of the cell permeant analogue 8-Br-cGMP. Between
10_li M and i0 M there is a direct dose-response relationship
with increasing [8-Br-cGMP] causing progressively greater in-
creases in renin secretion. With iO M 8-Br-cGMP, mean release
of renin is 102.5% above baseline (P < 0.01). At higher [8-Br-
cGMP] an inverse relationship with renin release was found, and
no significant increase in renin release occurred with the two
highest doses (10 M and 10 M) of the drug. Mean renin
release with iO M 8-Br-cGMP was only 6.3% above basal
release.
A similar pattern of response to the 8-Br-cGMP data was
obtained in studies using NP and APII (results not shown). NP,
studied over the range 10_in to iO M produced peak stimulation
of renin release at i0 M (RR = 179.2%; P < 0.001) but at iO M
NP the mean increase in renin release, although still significant,
was only 16.2% (P < 0.05) above baseline. Responses to APII,
which also increased renin release, were studied over the dose
range 10—14 M to i0 M. A peak response occurred at 10_b M
API! (R.R. = 174.5%;P < 0.01) but at iO M APII the increase
in renin release was only 23.7% above the baseline (P < 0.01).
Studies using MeB, an inhibitor of soluble guanylate cyclase
also yielded a biphasic pattern of response (Fig. 2). With 106 M
MeB (RR = 73.5%;P < 0.05) and with io M MB (RR =57.4%;
P < 0.01), basal renin release (100%) was significantly reduced
but i0 M MeB increased renin release (RR 128.7%; P <
0.01). No statistically significant changes were recorded with the
two lowest concentrations of MeB used.
The stimulatory role for the cGMP pathway in the regulation of
renin release was confirmed in a further series of experiments
(data not shown). The cGMP-specific phosphodiesterase inhibitor
MB22948 (10 M) potentiated renin release in response to NP
(10 M) by 214.1% (P < 0.001) and in response to 8-Br-cGMP
(10—6 M) by 156.6% (P < 0.05). MeB (10 M) attenuated the
response to NP (10 M) by 50.1% (P < 0.001) but, as expected,
did not have any effect on responses to 8-Br-cGMP (10—8 M).
LY83583 (10_6 M), a drug which lowers intracellular [cGMP],
reduced the stimulation of renin release by NP (10 M) by 73.7%
(P < 0.01) and also had no effect on 8-Br-cGMP (108 M)
stimulated renin release.
Discussion
The data presented primarily support the hypothesis that
cGMP is a stimulatory second messenger for renin release but
also provide evidence of a second, inhibitory pathway activated by
high drug doses. The experimental results were obtained using a
superfused collagenase dispersed rat kidney cortex cell prepara-
tion in which secondary effects on renin secretion mediated via
changes in smooth muscle tone, neural activity or kidney tubular
function were eliminated. In addition, the use of a superfusion
technique avoids the potential effects on renin secretion of the
accumulated secretory and metabolic products present in static
cell incubation protocols.
The analogue 8-Br-cGMP (Fig. 1), NP and AP!I stimulated
renin release at all doses used. Responses to 8-Br-cGMP and NP
were potentiated by the cGMP specific phosphodiesterase inhib-
itor MB22948. The increased renin secretion produced by NP was
markedly attenuated by the guanylate cyclase inhibitor MeB and
by LY83583, a drug which reduces intracellular [cGMP] partly by
suppressing guanylate cyclase [8]. As would be expected, MeB and
LY83583 did not affect the increase in renin release produced by
8-Br-cGMP. A stimulatory role for cGMP in the control of renin
release has previously been proposed on the basis of studies using
the isolated perfused rat kidney preparation [1, 2].
Some authors, using kidney cortex slice preparations, have
found evidence that cGMP is an inhibitory second messenger for
renin release [3—5]. We propose from the present study that there
are two separate and opposing pathways, a stimulatory pathway
activated by low concentrations of drugs and an inhibitory path-
way activated at high drug dose levels. Dose-response relation-
ships in this study had two distinct phases, a positive correlation
between low range drug doses and renin release and a negative
correlation between high range drug doses and renin release. This
is shown for 8-Br-cGMP in Figure 1, but very similar data were
obtained for NP and APII. Further evidence of an inhibitory
pathway involving cGMP is shown in Figure 2. The soluble
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6 Fig. 2. Effect of a range of concentrations of methylene blue on basal renin
release. Results are shown as mean SCM.
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guanylate cyclase inhibitor MeB, at 106 M and iO M, inhibited
basal renin release, suggesting blockade of a stimulatory pathway
for renin. However, 10 M MeB caused significant stimulation of
renin secretion, suggesting the existence of a cGMP-linked inhib-
itory pathway.
It seems likely that, under physiological conditions, the major
role for cGMP is as a stimulatory second messenger for renin and
that the inhibitory pathway modulates this role, perhaps via an
increase in intracellular [Ca}.
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